Human natural killer cell deficiencies

Current Opinion in Allergy and Clinical Immunology

Volumn 6, Issue 6, 2006, Pages 399-409

  Orange, Jordan S ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Cytotoxicity; Herpesviruses; Natural killer cell deficiency; Natural killer cells; Natural killer T cells; Primary immunodeficiency

Indexed keywords

ADAPTOR PROTEIN; CASPASE 8; DIPEPTIDYL PEPTIDASE I; I KAPPA B KINASE GAMMA; SNARE PROTEIN; SYNTAXIN;

AUTOIMMUNE DISEASE; B LYMPHOCYTE ACTIVATION; COMBINED IMMUNODEFICIENCY; CYTOTOXIC T LYMPHOCYTE; GENETIC ASSOCIATION; GRISCELLI SYNDROME; HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS; HUMAN; IMMUNE DEFICIENCY; INFECTION SENSITIVITY; KERATOSIS PALMOPLANTARIS; LYMPHOPROLIFERATIVE DISEASE; MISSENSE MUTATION; NATURAL KILLER T CELL; OCULAR ALBINISM; PRIORITY JOURNAL; REVIEW; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; T LYMPHOCYTE ACTIVATION; TARGET CELL; WISKOTT ALDRICH SYNDROME;

CYTOTOXICITY, IMMUNOLOGIC; GENETIC DISEASES, INBORN; HERPESVIRIDAE INFECTIONS; HUMANS; IMMUNOLOGIC DEFICIENCY SYNDROMES; KILLER CELLS, NATURAL;

EID: 33750800121     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/ACI.0b013e3280106b65     Document Type: Review

References (71)

1. Orange JS, Ballas ZK. Natural killer cells in human health and disease. Clin Immunol 2006; 118:1-10.
2. Wu J, Lanier LL. Natural killer cells and cancer. Adv Cancer Res 2003; 90:127-156.
3. French AR, Yokoyama WM. Natural killer cells and autoimmunity. Arthritis Res Ther 2004; 6:8-14.
4. Tay CH, Szomolanyi-Tsuda E, Welsh RM. Control of infections by NK cells. Curr Top Microbiol Immunol 1998; 230:193-220.
5. Orange JS. Human natural killer cell deficiencies and susceptibility to infection. Microbes Infect 2002; 4:1545-1558.
6. Chun HJ, Zheng L, Ahmad M, et al. Pleiotropic defects in lymphocyte activation caused by caspase-8 mutations lead to human immunodeficiency. Nature 2002; 419:395-399.
7. Su H, Bidere N, Zheng L, et al. Requirement for caspase-8 in NF-kappaB activation by antigen receptor. Science 2005; 307:1465-1468. Demonstration of caspase-8 requirement for human NK cell function. In particular cytotoxicity receptor ligation was linked to NF-κB activation through caspase 8.
8. Orange JS, Brodeur SR, Jain A, et al. Deficient natural killer cell cytotoxicity in patients with IKK-gamma/NEMO mutations. J Clin Invest 2002; 109:1501-1509.
9. Orange JS, Jain A, Ballas ZK, et al. The presentation and natural history of immunodeficiency caused by nuclear factor kappaB essential modulator mutation. J Allergy Clin Immunol 2004; 113:725-733.
10. Bidere N, Su HC, Lenardo MJ. Genetic disorders of programmed cell death in the immune system. Annu Rev Immunol 2006; 24:321-352.
11. Katano H, Cohen JI. Perforin and lymphohistiocytic proliferative disorders. Br J Haematol 2005; 128:739-750.
12. Orange JS. NK cell deficiency syndromes. In: Rose B, editor. UpToDate. Mass: Waltham; 2006.
13. Stinchcombe J, Bossi G, Griffiths GM. Linking albinism and immunity: the secrets of secretory lysosomes. Science 2004; 305:55-59.
14. Stepp SE, Dufourcq-Lagelouse R, Le Deist F, et al. Perforin gene defects in familial hemophagocytic lymphohistiocytosis. Science 1999; 286:1957-1959.
15. Feldmann J, Callebaut I, Raposo G, et al. Munc13-4 is essential for cytolytic granules fusion and is mutated in a form of familial hemophagocytic lymphohistiocytosis (FHL3). Cell 2003; 115:461-473.
16. zur Stadt U, Schmidt S, Kasper B, et al. Linkage of familial hemophagocytic lymphohistiocytosis (FHL) type-4 to chromosome 6q24 and identification of mutations in syntaxin 11. Hum Mol Genet 2005; 14:827-834. Novel linkage of the SNARE protein syntaxin-11 to the FHL phenotype in patients with diminished NK cell cytotoxicity.
17. Rudd E, Goransdotter Ericson K, Cheng C, et al. Spectrum and clinical implications of syntaxin 11 gene mutations in familial haemophagocytic lymphohistiocytosis: association with disease-free remissions and haematopoietic malignancies. J Med Genet 2006; 43:e14.
18. Ishii E, Ueda I, Shirakawa R, et al. Genetic subtypes of familial hemophagocytic lymphohistiocytosis: correlations with clinical features and cytotoxic T lymphocyte/NK cell functions. Blood 2005; 105:3442-3448.
19. Marcenaro S, Gallo F, Martini S, et al. Analysis of Natural killer cell function in familial hemophagocytic lymphohistiocytosis (FHL). Defective CD107a surface expression heralds Munc13-4 defect and discriminates between genetic subtypes of the disease. Blood, 2006. This article uses Munc13-4-deficient human NK cells to show the requirement of this protein in NK cell lytic granule fusion.
20. Clark RH, Stinchcombe JC, Day A, et al. Adaptor protein 3-dependent microtubule-mediated movement of lytic granules to the immunological synapse. Nat Immunol 2003; 4:1111-1120.
21. Fontana S, Parolini S, Vermi W, et al. Innate immunity defects in Hermansky-Pudlak type 2 syndrome. Blood 2006; 107:4857-4864. Demonstration that AP-3 is required for the normal formation and traffic of lytic granules in NK cells.
22. Enders A, Zieger B, Schwarz K, et al. Lethal hemophagocytic lymphohistiocytosis in Hermansky-Pudlak syndrome type II. Blood 2006; 108:81-87. Report of the HLH phenotype in HPS2 demonstrating the importance of the cytolytic defect resulting from AP-3 deficiency.
23. Pham CT, Ivanovich JL, Raptis SZ, et al. Papillon-Lefevre syndrome: correlating the molecular, cellular, and clinical consequences of cathepsin C/dipeptidyl peptidase I deficiency in humans. J Immunol 2004; 173:7277-7281.
24. Meade JL, de Wynter EA, Brett P, et al. A family with Papillon-Lefevre syndrome reveals a requirement for cathepsin C in granzyme B activation and NK cell cytolytic activity. Blood 2006; 107:3665-3668. This article demonstrates that NK cells require cathepsin C to process granzyme B and function fully in cytotoxicity, as well as that in vitro exposure to IL-2 obscures this phenotype. This also highlights the importance of evaluating ex-vivo NK cells without additional in-vitro manipulation.
25. Schmid JM, Junge SA, Hossle JP, et al. Transient hemophagocytosis with deficient cellular cytotoxicity, monoclonal immunoglobulin M gammopathy, increased T-cell numbers, and hypomorphic NEMO mutation. Pediatrics 2006; 117:e1049-e1056. First association of the HLH phenotype with NEMO deficiency attesting to the relevance of the cytolytic defect found in these patients.
26. Pandey R, Deering RP, Banerjee PP, Orange JS. Requirement for the classical pathway of NF-κB activation in NK cell cytolytic function. J Allergy Clin Immunol 2006; 117:S15.
27. Feldmann J, Le Deist F, Ouachee-Chardin M, et al. Functional consequences of perforin gene mutations in 22 patients with familial haemophagocytic lymphohistiocytosis. Br J Haematol 2002; 117:965-972.
28. Ueda I, Ishii E, Morimoto A, et al. Correlation between phenotypic heterogeneity and gene mutational characteristics in familial hemophagocytic lymphohistiocytosis (FHL). Pediatr Blood Cancer 2006; 46:482-488.
29. Risma KA, Frayer RW, Filipovich AH, Sumegi J. Aberrant maturation of mutant perforin underlies the clinical diversity of hemophagocytic lymphohistiocytosis. J Clin Invest 2006; 116:182-192. This article demonstrates that HLH-associated perforin missense gene mutations can lead to defective function because the resulting protein is incorrectly processed, rapidly degraded or incompletely matured. Certain of these are also shown to be associated with a later onset disease.
30. Santoro A, Cannella S, Trizzino A, et al. A single amino acid change A91V in perforin: a novel, frequent predisposing factor to childhood acute lymphoblastic leukemia? Haematologica 2005; 90:697-698.
31. Clementi R, Locatelli F, Dupre L, et al. A proportion of patients with lymphoma may harbor mutations of the perforin gene. Blood 2005; 105:4424-4428. Demonstrates an association between lymphoma susceptibility and perforin mutation underlining the tumor surveillance capacity of cytotoxic lymphocytes.
32. Katano H, Ali MA, Patera AC, et al. Chronic active Epstein-Barr virus infection associated with mutations in perforin that impair its maturation. Blood 2004; 103:1244-1252.
33. Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002; 295:2097-2100.
34. Kumaki S, Ishii N, Minegishi M, et al. Functional role of interleukin-4 (IL-4) and IL-7 in the development of X-linked severe combined immunodeficiency. Blood 1999; 93:607-612.
35. Ginn SL, Smyth C, Wong M, et al. A novel splice-site mutation in the common gamma chain (gammac) gene IL2RG results in X-linked severe combined immunodeficiency with an atypical NK+ phenotype. Hum Mutat 2004; 23:522-523.
36. Roberts JL, Lengi A, Brown SM, et al. Janus kinase 3 (JAK3) deficiency: clinical, immunologic, and molecular analyses of 10 patients and outcomes of stem cell transplantation. Blood 2004; 103:2009-2018.
37. Gilmour KC, Fujii H, Cranston T, et al. Defective expression of the interleukin-2/interleukin-15 receptor beta subunit leads to a natural killer cell-deficient form of severe combined immunodeficiency. Blood 2001; 98:877-879.
38. Markel G, Mussaffi H, Ling KL, et al. The mechanisms controlling NK cell autoreactivity in TAP2-deficient patients. Blood 2004; 103:1770-1778.
39. Markel G, Achdout H, Katz G, et al. Biological function of the soluble CEACAM1 protein and implications in TAP2-deficient patients. Eur J Immunol 2004; 34:2138-2148.
40. Kim S, Poursine-Laurent J, Truscott SM, et al. Licensing of natural killer cells by host major histocompatibility complex class I molecules. Nature 2005; 436:709-713.
41. Hanna J, Mussaffi H, Steuer G, et al. Functional aberrant expression of CCR2 receptor on chronically activated NK cells in patients with TAP-2 deficiency. Blood 2005; 106:3465-3473. Elegant proteomic analyses define increased CCR2 expression and function in TAP-2 deficiency, explain a particular pathologic consequence of the disease (NK cell accumulation), and suggest an adverse consequence of aberrant NK cell licensing.
42. Orange JS, Stone KD, Turvey SE, Krzewski K. The Wiskott-Aldrich syndrome. Cell Mol Life Sci 2004; 61:2361-2385.
43. Orange JS, Ramesh N, Remold-O'Donnell E, et al. Wiskott-Aldrich syndrome protein is required for NK cell cytotoxicity and colocalizes with actin to NK cell-activating immunologic synapses. Proc Natl Acad Sci U S A 2002; 99:11351-11356.
44. Gismondi A, Cifaldi L, Mazza C, et al. Impaired natural and CD16-mediated NK cell cytotoxicity in patients with WAS and XLT: ability of IL-2 to correct NK cell functional defect. Blood 2004; 104:436-443.
45. Orange JS, Harris KE, Andzelm MM, et al. The mature activating natural killer cell immunologic synapse is formed in distinct stages. Proc Natl Acad Sci U S A 2003; 100:14151-14156.
46. Huang W, Ochs HD, Dupont B, Vyas YM. The Wiskott-Aldrich syndrome protein regulates nuclear translocation of NFAT2 and NF-kappa B (RelA) independently of its role in filamentous actin polymerization and actin cytoskeletal rearrangement. J Immunol 2005; 174:2602-2611.
47. Bonilla FA, Bernstein IL, Khan DA, et al. Practice parameter for the diagnosis and management of primary immunodeficiency. Ann Allergy Asthma Immunol 2005; 94:S1-63.
48. Cederbrant K, Marcusson-Stahl M, Condevaux F, Descotes J. NK-cell activity in immunotoxicity drug evaluation. Toxicology 2003; 185:241-250.
49. Zorrilla EP, Luborsky L, McKay JR, et al. The relationship of depression and stressors to immunological assays: a meta-analytic review. Brain Behav Immun 2001; 15:199-226.
50. Vossen MT, Biezeveld MH, de Jong MD, et al. Absence of circulating natural killer and primed CD8+ cells in life-threatening varicella. J Infect Dis 2005; 191:198-206. Demonstrates a very transient deficiency of natural killer cells in the context of severe VZV infection highlighting the need for longitudinal evaluations of a patient suspected of an isolated NK cell deficiency.
51. Levy O, Orange JS, Hibberd P, et al. Disseminated varicella infection due to the vaccine strain of varicella-zoster virus, in a patient with a novel deficiency in natural killer T cells. J Infect Dis 2003; 188:948-953.
52. Biron CA, Byron KS, Sullivan JL. Severe herpesvirus infections in an adolescent without natural killer cells. N Engl J Med 1989; 320:1731-1735.
53. Wendland T, Herren S, Yawalkar N, et al. Strong αβ and γδ TCR response in a patient with disseminated mycobacterium avium infection and lack of NK cells and monocytopenia. Immunol Lett 2000; 72:75-82.
54. Bernard F, Picard C, Cormier-Daire V, et al. A novel developmental and immunodeficiency syndrome associated with intrauterine growth retardation and a lack of natural killer cells. Pediatrics 2004; 113:136-141.
55. Eidenschenk C, Jouanguy E, Mention J-J, et al. A novel primary immunodeficiency associated with impaired lymphocyte survival and secondary neutropenia [abstract]. Proceedings of the 9th Workshop of the Society for Natural Immunity; 4-8 November 2005; Kauai, Hawaii; A054.
56. Etzioni A, Eidenschenk C, Katz R, et al. Fatal varicella associated with selective natural killer cell deficiency. J Pediatr 2005; 146:423-425. Clear new case of ANKD demonstrating susceptibility to herpesvirus.
57. Notarangelo LD, Mazzolari E. Natural killer cell deficiencies and severe varicella infection. J Pediatr 2006; 148:563-564.
58. Eidenschenk C, Dunne J, Jouanguy E, et al. A novel primary immunodeficiency with specific natural-killer cell deficiency maps to the centromeric region of chromosome 8. Am J Hum Genet 2006; 78:721-727. Large familial cohort with ANKD and linkage of the phenotype to chromosome 8p11.23-q11.21. It is likely that this region will contain a specific gene that can result in ANKD.
59. Jawahar S, Moody C, Chan M, et al. Natural killer (NK) cell deficiency associated with an epitope-deficient Fc receptor type IIIA (CD16-II). Clin Exp Immunol 1996; 103:408-413.
60. de Vries E, Koene HR, Vossen JM, et al. Identification of an unusual Fcg receptor IIIa (CD16) on natural killer cells in a patient with recurrent infections. Blood 1996; 88:3022-3027.
61. Fleisher G, Starr S, Koven N, et al. A nonx-linked syndrome with susceptibility to severe Epstein-Barr virus infections. J Pediatr 1982; 100:727-730.
62. Komiyama A, Kawai H, Yabuhara A, et al. Natural killer cell immunodeficiency in siblings: defective killing in the absence of natural killer cytotoxic factor activity in natural killer and lymphokine-activated killer cytotoxicities. Pediatrics 1990; 85:323-330.
63. Aoukaty A, Lee I-F, Wu J, Tan R. Chronic active Epstein-Barr virus infection associated with low expression of leukocyte-associated immunoglobulin-like receptor-1 (LAIR-1) on natural killer cells. J Clin Immunol 2003; 23:141-145.
64. Yachie A, Kanegane H, Kasahara Y. Epstein-Barr virus-associated T-/natural killer cell lymphoproliferative diseases. Semin Hematol 2003; 40:124-132.
65. Whiteside TL, Friberg D. Natural killer cells and natural killer cell activity in chronic fatigue syndrome. Am J Med 1998; 105:27S-34S.
66. Maher KJ, Klimas NG, Fletcher MA. Chronic fatigue syndrome is associated with diminished intracellular perforin. Clin Exp Immunol 2005; 142:505-511.
67. Gazit R, Garty BZ, Monselise Y, et al. Expression of KIR2DL1 on the entire NK cell population: a possible novel immunodeficiency syndrome. Blood 2004; 103:1965-1966.
68. Parham P. MHC class I molecules and KIRs in human history, health and survival. Nat Rev Immunol 2005; 5:201-214.
69. Ballas ZK, Turner JM, Turner DA, et al. A patient with simultaneous absence of "classical" natural killer cells (CD3-, CD16+, and NKH1+) and expansion of CD3+, CD4-, CD8-, NKH1+ subset. J Allergy Clin Immunol 1990; 85:453-459.
70. Akiba H, Motoki Y, Satoh M, et al. Recalcitrant trichophytic granuloma associated with NK-cell deficiency in a SLE patient treated with corticosteroid. Eur J Dermatol 2001; 11:58-62.
71. Komiyama A, Kawai H, Yamada S, et al. A killing defect of natural killer cells with the absence of natural killer cytotoxic factors in a child with Hodgkin's disease. Blood 1987; 69:1686-1690.